Long-Term View
Two long-term views: evidence for investments, followed by everyday branded products with documented historical comparisons.
DAILY EDITORIAL · 8 September 2026
Investments and everyday merchandise
Explore two separate ideas: long-term investments, and ordinary branded merchandise available at retail now.
Research, not personal financial advice. Download the research record.
Long Term investments
Current evidence and original historical scores keep their own dates. Open a review for the ten investment traits.
Cloudflare
Current partial review: · 1 of 10 traits supported.
Historical complete review: · 9 of 10 traits. This older score is not a current score.
The last complete review found growing demand for website security and services used by software makers, backed by strong operating results.
Changed since the last full check: Cloudflare announced invitation-only Vulnerability Discovery and Remediation with OpenAI Daybreak on September 3. This adds a concrete product distribution step to the rechecked Q1/Q2 demand evidence. Early access for selected Enterprise customers does not demonstrate adoption, incremental revenue or superior margins. The original quarterly margin and loss concerns remain.
Cloudflare announced invitation-only Vulnerability Discovery and Remediation with OpenAI Daybreak on September 3. This adds a concrete product distribution step to the rechecked Q1/Q2 demand evidence. Revenue rose from $639.8m in Q1 to $696.1m in Q2; annual growth increased from 34% to 36%. Current RPO growth increased from 34% to 35%. Q2 operating cash was $117.6m and free cash flow $56.4m. Early access for selected Enterprise customers does not demonstrate adoption, incremental revenue or superior margins. The original quarterly margin and loss concerns remain.
Historical comparison: Not shown yet because the archive has not completed the same ten checks for each historical case.
Open each saved trait
| Trait | Check | Saved evidence |
|---|---|---|
| A reason expectations may change | Unknown / incomplete evidence | A specific invitation-only service is announced; adoption and revenue impact remain unknown.; A concrete product distribution step: confirmed. Cloudflare announced invitation-only Vulnerability Discovery and Remediation with OpenAI Daybreak on September 3. This adds a concrete product distribution step to the rechecked Q1/Q2 demand evidence. |
| Demand is speeding up | Confirmed in current evidence | Two primary quarterly reports show continuing revenue and contracted-demand growth; multiyear continuation remains uncertain.; Revenue, orders, bookings or unit sales are growing: confirmed. Q1 and Q2 revenue and RPO comparisons support continuing demand. |
| Supply cannot respond quickly | Unknown / incomplete evidence | The captured financial reports do not quantify competitor capacity, switching costs or tradeable-share scarcity. |
| A small base with a long runway | Unknown / incomplete evidence | No current valuation and defensible addressable-market comparison was completed. |
| A better product with a lasting edge | Unknown / incomplete evidence | Revenue growth does not establish a lasting advantage against comparable competing products. |
| Growth turns into lasting value | Unknown / incomplete evidence | Positive free cash flow supports value capture, while deteriorating annual margins oppose a broad improvement claim.; Free cash flow is positive or improving: confirmed. Q2 free cash flow was positive and higher than the prior-year quarter.; Margins are improving: contradicted. Year-on-year Q2 GAAP gross and operating margins deteriorated; specify this comparison, not an unqualified all-period claim. |
| Owners can keep building | Unknown / incomplete evidence | Current ownership, incentives and capital-allocation returns were not fully verified. |
| Built to survive setbacks | Unknown / incomplete evidence | Cash is substantial, but liabilities, commitments and a severe-downturn stress test were not fully reviewed. |
| The numbers and market agree | Unknown / incomplete evidence | A current issuer-specific price/benchmark study and repeated expectations comparison are absent. |
| The wider environment may accelerate it | Unknown / incomplete evidence | Current leverage, options positioning and market-flow amplification were not measured. |
Future check: No dated forecast is active.
Open the evidence and limits
Claim: Cloudflare: 1 of 10 traits have supporting evidence in the partial current review at 8 Sept 2026.
Supporting reports
What argues against it
- Cloudflare announced invitation-only Vulnerability Discovery and Remediation with OpenAI Daybreak on September 3. This adds a concrete product distribution step to the rechecked Q1/Q2 demand evidence. Revenue rose from $639.8m in Q1 to $696.1m in Q2; annual growth increased from 34% to 36%. Current RPO growth increased from 34% to 35%. Q2 operating cash was $117.6m and free cash flow $56.4m. Early access for selected Enterprise customers does not demonstrate adoption, incremental revenue or superior margins. The original quarterly margin and loss concerns remain.
- Not shown yet because the archive has not completed the same ten checks for each historical case.
- The latest source checks show specific supporting and opposing facts. The August 5 full review remains historical; missing evidence prevents a new complete score, rank or price forecast.
- Where the reports came from
- Not recorded
- Languages
- Not recorded
- How recent
- Current partial review: 8 Sept 2026
- Similar earlier cases
- Not measured
How sure is OTR?
Insufficient evidenceNo confidence number is shown because source quality, independent reports, freshness, opposing evidence, earlier comparisons, time accuracy are not fully measured.
The six measured checks are multiplied together. This evidence score is not the chance a prediction will be right.
- Source quality: Not fully measured.
- Independent reports: Not fully measured.
- Freshness: Not fully measured.
- Opposing evidence: Not fully measured.
- Earlier comparisons: Not fully measured.
- Time accuracy: Not fully measured.
Where this appears
Rocket Lab
Current partial review: · 1 of 10 traits supported.
Historical complete review: · 8 of 10 traits. This older score is not a current score.
The last complete review found launches, paying customers and many customer orders, while major programmes still had to grow much larger.
Changed since the last full check: The current issuer index reports its 94th Electron mission succeeded on September 2. The August 10 Q2 release remains the latest financial release identified in this check. A successful mission count is execution evidence, not proof of Neutron delivery, sustainable cash generation or a fair entry valuation.
The current issuer index reports its 94th Electron mission succeeded on September 2. The August 10 Q2 release remains the latest financial release identified in this check. Q1 revenue was $200.3m and Q2 $234.1m; backlog rose from about $2.2bn to $2.36bn. Q2 GAAP operating loss narrowed to $57.514m from $59.639m a year earlier. A successful mission count is execution evidence, not proof of Neutron delivery, sustainable cash generation or a fair entry valuation.
Historical comparison: Not shown yet because the archive has not completed the same ten checks for each historical case.
Open each saved trait
| Trait | Check | Saved evidence |
|---|---|---|
| A reason expectations may change | Unknown / incomplete evidence | Announced products, acquisitions and a future Neutron launch are catalysts requiring execution evidence. |
| Demand is speeding up | Confirmed in current evidence | Primary Q1 and Q2 reports show revenue and backlog growth across periods; order conversion remains uncertain.; Revenue, orders, bookings or unit sales are growing: confirmed. Both quarterly revenue and backlog increased between the captured reports. |
| Supply cannot respond quickly | Unknown / incomplete evidence | Backlog does not quantify industry capacity scarcity or how quickly competitors can respond. |
| A small base with a long runway | Unknown / incomplete evidence | No current market-value versus accessible-market test was completed. |
| A better product with a lasting edge | Unknown / incomplete evidence | Product breadth and contracts do not independently establish enduring superiority or competitive returns. |
| Growth turns into lasting value | Unknown / incomplete evidence | Narrower operating losses support efficiency, but operating cash burn and share issuance oppose self-funding growth.; Operating cash can support needed investment: contradicted. First-half operating cash was negative, alongside external financing inflows.; Share or token dilution is limited: unknown. The approximately 10.05% rise in ordinary shares is an explicit dilution warning; no rubric threshold defines limited. |
| Owners can keep building | Unknown / incomplete evidence | M&A announcements and funding do not yet prove integration discipline or successful future delivery.; Observed operating execution: confirmed. Issuer index reports successful 94th Electron mission September 2; ownership and incentive alignment remain unknown. |
| Built to survive setbacks | Unknown / incomplete evidence | Cash must be assessed against acquisition commitments, launch development costs and funding dependence. |
| The numbers and market agree | Unknown / incomplete evidence | No repeated comparable expectations and issuer-specific relative-market test was completed. |
| The wider environment may accelerate it | Unknown / incomplete evidence | Current options, leverage and speculative flow evidence was not captured. |
Future check: No dated forecast is active.
Open the evidence and limits
Claim: Rocket Lab: 1 of 10 traits have supporting evidence in the partial current review at 8 Sept 2026.
Supporting reports
What argues against it
- The current issuer index reports its 94th Electron mission succeeded on September 2. The August 10 Q2 release remains the latest financial release identified in this check. Q1 revenue was $200.3m and Q2 $234.1m; backlog rose from about $2.2bn to $2.36bn. Q2 GAAP operating loss narrowed to $57.514m from $59.639m a year earlier. A successful mission count is execution evidence, not proof of Neutron delivery, sustainable cash generation or a fair entry valuation.
- Not shown yet because the archive has not completed the same ten checks for each historical case.
- The latest source checks show specific supporting and opposing facts. The August 5 full review remains historical; missing evidence prevents a new complete score, rank or price forecast.
- Where the reports came from
- Not recorded
- Languages
- Not recorded
- How recent
- Current partial review: 8 Sept 2026
- Similar earlier cases
- Not measured
How sure is OTR?
Insufficient evidenceNo confidence number is shown because source quality, independent reports, freshness, opposing evidence, earlier comparisons, time accuracy are not fully measured.
The six measured checks are multiplied together. This evidence score is not the chance a prediction will be right.
- Source quality: Not fully measured.
- Independent reports: Not fully measured.
- Freshness: Not fully measured.
- Opposing evidence: Not fully measured.
- Earlier comparisons: Not fully measured.
- Time accuracy: Not fully measured.
Where this appears
Tempus AI
Current partial review: · 2 of 10 traits supported.
Historical complete review: · 8 of 10 traits. This older score is not a current score.
The last complete review found growing use of tools that help organise medical information, alongside continuing losses and the risk of customers leaving.
Changed since the last full check: The August 24 issuer announcement adds FDA clearance for ECG-PH, its third cleared cardiovascular device, to the previously checked Q2 evidence. The product is not a stand-alone pulmonary-hypertension diagnostic. Clearance alone does not establish adoption, reimbursement, clinical outcomes or cash profitability.
The August 24 issuer announcement adds FDA clearance for ECG-PH, its third cleared cardiovascular device, to the previously checked Q2 evidence. Q2 revenue was $382.5m, up 22%. The issuer reports oncology volume growth of 31%, versus 28% last quarter, and MRD tests of 9,000 versus 6,500. It reports FDA approval of tumor-only xT CDx and a delivered AstraZeneca model. The product is not a stand-alone pulmonary-hypertension diagnostic. Clearance alone does not establish adoption, reimbursement, clinical outcomes or cash profitability.
Historical comparison: Not shown yet because the archive has not completed the same ten checks for each historical case.
Open each saved trait
| Trait | Check | Saved evidence |
|---|---|---|
| A reason expectations may change | Confirmed in current evidence | The issuer reports August 24 FDA clearance for ECG-PH. This confirms a regulatory milestone in issuer evidence, not an independent review of the FDA letter or commercial adoption.; Regulatory approval, deregulation or government support: confirmed. Issuer reports the specific FDA tumor-only assay approval; this is issuer evidence, not an independently retained FDA decision letter.; Regulatory clearance extends product scope: confirmed. The August 24 issuer announcement adds FDA clearance for ECG-PH, its third cleared cardiovascular device, to the previously checked Q2 evidence. The product is not a stand-alone pulmonary-hypertension diagnostic. Clearance alone does not establish adoption, reimbursement, clinical outcomes or cash profitability. |
| Demand is speeding up | Confirmed in current evidence | The report provides prior-quarter comparisons for oncology and MRD testing; total revenue growth nevertheless slowed.; Usage, engagement or transactions are growing: confirmed. The report compares oncology and MRD testing with the preceding quarter. |
| Supply cannot respond quickly | Unknown / incomplete evidence | No quantified supply constraint, data exclusivity or competitor-capacity assessment was completed. |
| A small base with a long runway | Unknown / incomplete evidence | Current valuation and a justified market penetration comparison are not established. |
| A better product with a lasting edge | Unknown / incomplete evidence | Approval and delivery support product capability but do not establish a durable comparative moat. |
| Growth turns into lasting value | Unknown / incomplete evidence | Investment gains explain positive net income while operations consume cash; lasting self-funding remains unproved.; Operating cash can support needed investment: contradicted. First-half operating cash was negative; positive GAAP net income depended on nonoperating investment gains. |
| Owners can keep building | Unknown / incomplete evidence | The acquisition agreement does not establish completed integration, long-term incentives or capital returns. |
| Built to survive setbacks | Unknown / incomplete evidence | Cash balances, debt and acquisition obligations require a complete liquidity and financing review. |
| The numbers and market agree | Unknown / incomplete evidence | Testing growth lacks an accompanying current relative-price and repeated-expectations study. |
| The wider environment may accelerate it | Unknown / incomplete evidence | No current market-positioning or leverage amplification evidence was reviewed. |
Future check: No dated forecast is active.
Open the evidence and limits
Claim: Tempus AI: 2 of 10 traits have supporting evidence in the partial current review at 8 Sept 2026.
Supporting reports
What argues against it
- The August 24 issuer announcement adds FDA clearance for ECG-PH, its third cleared cardiovascular device, to the previously checked Q2 evidence. Q2 revenue was $382.5m, up 22%. The issuer reports oncology volume growth of 31%, versus 28% last quarter, and MRD tests of 9,000 versus 6,500. It reports FDA approval of tumor-only xT CDx and a delivered AstraZeneca model. The product is not a stand-alone pulmonary-hypertension diagnostic. Clearance alone does not establish adoption, reimbursement, clinical outcomes or cash profitability.
- Not shown yet because the archive has not completed the same ten checks for each historical case.
- The latest source checks show specific supporting and opposing facts. The August 5 full review remains historical; missing evidence prevents a new complete score, rank or price forecast.
- Where the reports came from
- Not recorded
- Languages
- Not recorded
- How recent
- Current partial review: 8 Sept 2026
- Similar earlier cases
- Not measured
How sure is OTR?
Insufficient evidenceNo confidence number is shown because source quality, independent reports, freshness, opposing evidence, earlier comparisons, time accuracy are not fully measured.
The six measured checks are multiplied together. This evidence score is not the chance a prediction will be right.
- Source quality: Not fully measured.
- Independent reports: Not fully measured.
- Freshness: Not fully measured.
- Opposing evidence: Not fully measured.
- Earlier comparisons: Not fully measured.
- Time accuracy: Not fully measured.
Where this appears
Solana
Current partial review: · 1 of 10 traits supported.
Historical complete review: · 6 of 10 traits. This older score is not a current score.
The last complete review found an active online network and many uses, but company accounts cannot show how that activity will affect its price.
Changed since the last full check: The September 4 foundation roundup reports more than $4bn of real-world assets and a record 216 million non-vote transactions in one day in August. This is new retained adoption evidence; the fresh status response is separately operational. These are foundation-reported ecosystem measures, not independently reconciled fees or holder returns. Addresses and transactions are not equivalent to paying users, and infrastructure adoption does not establish SOL valuation.
The September 4 foundation roundup reports more than $4bn of real-world assets and a record 216 million non-vote transactions in one day in August. This is new retained adoption evidence; the fresh status response is separately operational. These are foundation-reported ecosystem measures, not independently reconciled fees or holder returns. Addresses and transactions are not equivalent to paying users, and infrastructure adoption does not establish SOL valuation.
Historical comparison: Not shown yet because the archive has not completed the same ten checks for each historical case.
Open each saved trait
| Trait | Check | Saved evidence |
|---|---|---|
| A reason expectations may change | Unknown / incomplete evidence | The roundup identifies payment and tokenization deployments, but no measured repricing catalyst or adoption-to-token-value link is established. |
| Demand is speeding up | Confirmed in current evidence | The September 4 foundation roundup reports new August activity records and RWA adoption. Confirmed refers to retained attributed issuer evidence, not an independent audit or recurring token revenue.; Usage or transactions growing: confirmed. Foundation reports 216 million non-vote transactions in one day and 1.32 billion in August 17–23; bot activity and sustainable economic use are not independently separated. |
| Supply cannot respond quickly | Unknown / incomplete evidence | Current token issuance, unlocks and concentration were not measured from retained original data. |
| A small base with a long runway | Unknown / incomplete evidence | No current market-value versus economically addressable-use test was completed. |
| A better product with a lasting edge | Unknown / incomplete evidence | Operational status does not compare performance, costs or switching incentives against competing networks. |
| Growth turns into lasting value | Unknown / incomplete evidence | Current fees, burn, issuance and token-holder value capture were not independently reconciled. |
| Owners can keep building | Unknown / incomplete evidence | Validator, development funding and governance incentive alignment were not assessed. |
| Built to survive setbacks | Unknown / incomplete evidence | A healthy status at one instant is insufficient to establish sustained security or crisis resilience. |
| The numbers and market agree | Unknown / incomplete evidence | Price candles alone do not establish adoption fundamentals or a complete benchmark comparison. |
| The wider environment may accelerate it | Unknown / incomplete evidence | Current leverage, derivatives positioning and token flow amplification were not measured. |
Future check: No dated forecast is active.
Open the evidence and limits
Claim: Solana: 1 of 10 traits have supporting evidence in the partial current review at 8 Sept 2026.
Supporting reports
What argues against it
- The September 4 foundation roundup reports more than $4bn of real-world assets and a record 216 million non-vote transactions in one day in August. This is new retained adoption evidence; the fresh status response is separately operational. These are foundation-reported ecosystem measures, not independently reconciled fees or holder returns. Addresses and transactions are not equivalent to paying users, and infrastructure adoption does not establish SOL valuation.
- Not shown yet because the archive has not completed the same ten checks for each historical case.
- The latest source checks show specific supporting and opposing facts. The August 5 full review remains historical; missing evidence prevents a new complete score, rank or price forecast.
- Where the reports came from
- Not recorded
- Languages
- Not recorded
- How recent
- Current partial review: 8 Sept 2026
- Similar earlier cases
- Not measured
How sure is OTR?
Insufficient evidenceNo confidence number is shown because source quality, independent reports, freshness, opposing evidence, earlier comparisons, time accuracy are not fully measured.
The six measured checks are multiplied together. This evidence score is not the chance a prediction will be right.
- Source quality: Not fully measured.
- Independent reports: Not fully measured.
- Freshness: Not fully measured.
- Opposing evidence: Not fully measured.
- Earlier comparisons: Not fully measured.
- Time accuracy: Not fully measured.
Where this appears
LONG TERM · EVERYDAY MERCHANDISE
Everyday merchandise to watch
Ordinary branded products available at retail now, compared with the original retail products and their later collector sales. Counterexamples show why familiar traits alone can fail. Shared traits give us a reason to investigate; they do not establish a future price.
Traits to compare
- Ordinary practical or play use. Establish that both products served an everyday purpose when sold. Being usable does not establish collector demand.
- Identifiable model and design. Named models and distinguishable designs permit a comparison; broad brand names and random assortments do not.
- Comparable product category. Compare construction sets with construction sets, digital pets with digital pets and watches with watches.
- Continuing maker and product tradition. Document a continuing brand or product family. Longevity alone can coexist with modest resale values.
- Equivalent early historical position. Check whether a current product actually shares an early-generation distinction, rather than borrowing it from an older object.
- Evidence of a closed supply. Require an actual production-ending or finite-run record. Current stock levels and household limits are not production totals.
- Measured preservation scarcity. Distinguish fragile or easily lost parts from evidence that few complete examples survive. A pristine auction lot is not a population study.
- Measured collector demand growth. Require repeated comparable sales or other direct demand evidence. A single completed sale cannot establish a trend.
3 everyday products in this review
Checked . Ordered by brand, product and model. This 8 September review revisits the three exact ordinary retail models in the preceding catalog. All three were rechecked at retail. Earlier rejected suggestions remain in the preserved 7 September catalog; this finite review is not a claim to cover every product on sale.
Bandai · Digital pet toy
Original Tamagotchi Sakura
US$22.99 · United States · Ordinary retail
A battery-powered pocket pet for feeding, care and play, carried on its attached chain.
View the exact retail product · Checked
Historical comparison: Original Bandai Tamagotchi (1997 retail generation). Bandai dates the Japanese launch to 1996 and the worldwide rollout to May 1997, including toy-store retail. A later manufacturer history documents mass-market success. The exact original 1997 MSRP and original purchase receipts for these sold units are unverified. Comparison limit: A close digital-pet match with modest historical results: a used 1997 unit displayed US$23 and a sealed auction example US$50. These are separate conditions, not evidence of exponential growth.
4 of 8 shared traits documented: Ordinary practical or play use, Identifiable model and design, Comparable product category, Continuing maker and product tradition
Comparison check — appreciation is not established. Counterexample: strong product similarities and nostalgia can coexist with modest later sale prices. This is a useful control in the watchlist, not an appreciation call.
Compare the traits and original evidence
Exact model: 42886. Fresh visible retail product check on 8 September Singapore time: US$22.99, Availability In Stock and Add to cart. The web text extractor also exposed a hidden Sold out label; actual visible product DOM resolves this observation.
| Trait | Historical product at original retail | Everyday product now | Evidence state |
|---|---|---|---|
| Ordinary practical or play use | The 1997 device launched through toy retail for virtual-pet play. | A standard portable virtual-pet toy for daily care and games. | Shared trait supported |
| Identifiable model and design | A named original 1997 Bandai device, with shell differences retained. | Manufacturer identifies the Sakura shell as 42886. | Shared trait supported |
| Comparable product category | The original product was a portable digital pet. | Original programming in a portable digital-pet device. | Shared trait supported |
| Continuing maker and product tradition | Bandai identifies its 1996/1997 launch history. | Bandai reproduces its original digital-pet experience. | Shared trait supported |
| Equivalent early historical position | The historical units belonged to the initial worldwide generation. | A later Sakura shell using earlier programming. | Important difference |
| Evidence of a closed supply | Mass-market rollout is documented; exact surviving supply is unknown. | No confirmed limited run or production-end record. | Not established |
| Measured preservation scarcity | Sealed and used examples exist; no survival-rate study was collected. | Battery electronics and daily handling create risks, not measured scarcity. | Not established |
| Measured collector demand growth | Two condition-different results cannot measure a market trend. | No repeated sale series establishes demand growth for Sakura. | Not established |
What happened to the historical product
A seller-described working, used 1997 unit sold on eBay on 20 June 2026 with a displayed US$23 price; batteries were absent and listed shipping was US$6.50. Separately, Heritage displayed US$50 on 18 January 2026 for a sealed 1997 example with mild box wear and a25% buyer premium. Heritage title and description disagree about its colors; no color-variant inference is made. Seller net, taxes and any buyer-specific charges are unknown.
Tama History · Tama Old · Tama Used
Why the comparison could fail: Sakura is a later shell, not an original 1997 unit. Reproduction of the old experience provides substitutes. Battery condition, functionality, packaging and authentication matter; eBay attribution is seller supplied. Original MSRP is missing, so neither a historical return nor future target is calculated.
Next check: At the next edition, recheck this exact retail SKU, market, price and availability. Revisit the original historical comparison only when independently verified new sale evidence arrives; do not infer a return from undisclosed Best Offer settlement.
LEGO · Construction toy
Medieval Horse Knight Castle
SGD 189.90 · Singapore · Ordinary retail
A retail building-and-play set that rebuilds into a castle, knight tournament or medieval town.
View the exact retail product · Checked
Historical comparison: LEGO King's Castle 6080 (1984). An original medieval construction/play set with minifigures, movable fortress elements and accessories. The auction house describes its 1984 retail-set identity retrospectively; the original MSRP is unverified. Comparison limit: A close castle-set comparison, but the US$1,937.50 historical sale had unused, partly factory-sealed contents. Original retail price is unverified; no return multiple is established.
4 of 8 shared traits documented: Ordinary practical or play use, Identifiable model and design, Comparable product category, Continuing maker and product tradition
Research candidate — future value is unproven. A research candidate because it closely matches the historical product category. The available evidence supports a comparison, not a prediction of appreciation.
Compare the traits and original evidence
Exact model: 31168. Fresh visible retail product check on 8 September Singapore time: S$189.90, exact set31168, Available now and Add to Bag.
| Trait | Historical product at original retail | Everyday product now | Evidence state |
|---|---|---|---|
| Ordinary practical or play use | 6080 was a medieval construction/play set. | Designed for building and imaginative play. | Shared trait supported |
| Identifiable model and design | The historical set is identified as 6080. | Exact model 31168 and named medieval design. | Shared trait supported |
| Comparable product category | A castle with components, figures and accessories. | A castle made from interlocking components and figures. | Shared trait supported |
| Continuing maker and product tradition | The comparison was a LEGO medieval set in 1984. | LEGO currently sells a medieval play set. | Shared trait supported |
| Equivalent early historical position | 6080 belonged to the early Castle line. | A current three-in-one design after decades of Castle products. | Important difference |
| Evidence of a closed supply | 1984 identity is known; an original production-total record was not found. | No production-end date or total run established. | Not established |
| Measured preservation scarcity | This sale describes preserved contents, not the surviving population. | Many pieces can be lost, but survivor rates are unknown. | Not established |
| Measured collector demand growth | One preserved example cannot establish demand growth. | No repeated comparable resale series for 31168 was collected. | Not established |
What happened to the historical product
Heritage sold an open-box example for a displayed US$1,937.50 on 17 May 2026. Contents were unused, with many parts still factory sealed; the box had moderate wear and window damage. The lot states a 25% buyer premium. This is the house-displayed result, not seller proceeds or a result for a normally played-with set.
Why the comparison could fail: Different design and generation; unknown production totals and original cost baseline. Preserved contents, packaging and condition materially affect the cited sale. Modern substitutes and future reissues may limit demand. Storage, fees, shipping and inflation prevent treating gross auction prices as profit.
Next check: At the next edition, recheck this exact retail SKU, market, price and availability. Revisit the original historical comparison only when independently verified new sale evidence arrives; do not infer a return from undisclosed Best Offer settlement.
Swatch · Everyday wristwatch
ONCE AGAIN
SGD 115.00 · Singapore · Ordinary retail
A quartz wristwatch with time and day-date display, a black case and strap.
View the exact retail product · Checked
Historical comparison: Swatch BLACK MAGIC GB101, seller attributed to 1983. Swatch Group describes its 1983 launch as a low-cost Swiss watch built through automated production. Swatch confirms the BLACK MAGIC model identity; the completed listing attributes this specimen to 1983. The original GB101 price and individual manufacturing date are not independently verified. Comparison limit: The 1983-attributed GB101 listing is marked sold, but shows US$80 or Best Offer. The accepted amount is undisclosed, so this is an incomplete-evidence control, not a verified US$80 sale or appreciation result.
4 of 8 shared traits documented: Ordinary practical or play use, Identifiable model and design, Comparable product category, Continuing maker and product tradition
Comparison check — appreciation is not established. An incomplete-evidence control: the old model is identifiable and a listing completed, but its sale amount is undisclosed. Familiar traits cannot fill that evidence gap or justify a future price claim.
Compare the traits and original evidence
Exact model: GB743-S26. Fresh visible retail product check on 8 September Singapore time: S$115.00, exact GB743-S26, Add to cart. This direct observation supersedes the model initial S$84 claim.
| Trait | Historical product at original retail | Everyday product now | Evidence state |
|---|---|---|---|
| Ordinary practical or play use | Swatch began as a low-cost practical wristwatch. | A quartz watch for time and date in everyday wear. | Shared trait supported |
| Identifiable model and design | Swatch archive identifies BLACK MAGIC GB101. | Official reference GB743-S26 is named ONCE AGAIN. | Shared trait supported |
| Comparable product category | The comparison is another Swatch wristwatch. | A Swatch wristwatch. | Shared trait supported |
| Continuing maker and product tradition | Manufacturer history dates the brand launch to 1983. | The same maker currently sells its everyday watch range. | Shared trait supported |
| Equivalent early historical position | The sold specimen is attributed to the early 1983 collection; that year is seller supplied. | A current reference after decades of Swatch production. | Important difference |
| Evidence of a closed supply | Historical production and surviving reference totals were not verified. | Current availability does not establish total production or retirement. | Not established |
| Measured preservation scarcity | A used survivor is documented; no survivor-population data exists here. | Wear and battery maintenance do not establish future scarcity. | Not established |
| Measured collector demand growth | One completed listing with an undisclosed settlement cannot establish demand growth. | No comparable resale series was collected for this reference. | Not established |
What happened to the historical product
eBay marks the seller-attributed 1983 GB101 listing as sold on 10 July 2026. The original listing shows US$80 or Best Offer; the accepted offer and actual settlement are unverified. Listed shipping is US$10.95. It is used, without original box or papers. This observation proves a completed listing exists, not an exact sale amount, authentication, seller proceeds or a historical return.
Swatch History · Swatch Identity · Swatch Old
Why the comparison could fail: Different dial, reference and strap materials; continuous substitutes may limit demand. Seller dating and authenticity require further verification. Missing original retail price, transaction costs and inflation prevent a return calculation. Current Singapore retail and historical US-dollar prices are not a direct performance comparison.
Next check: At the next edition, recheck this exact retail SKU, market, price and availability. Revisit the original historical comparison only when independently verified new sale evidence arrives; do not infer a return from undisclosed Best Offer settlement.